Hypoxia, angiogenesis, and lung cancer.
Lung cancer is responsible for more deaths than any other cancer in America. As a result, novel ways to treat it are needed to improve patient outcomes. A tumor must form new blood vessels to grow and metastasize to distant sites; this angiogenesis is mediated by factors such as vascular endothelial growth factor (VEGF). Because it increases VEGF levels, hypoxia has been thought to be a primary trigger of angiogenesis. Tumor hypoxia and higher levels of serum markers of angiogenesis have been associated with poor prognosis in non-small cell lung cancer (NSCLC). In recent years, antiangiogenic compounds have been developed and tested in various solid malignancies, including NSCLC, for which bevacizumab, a monoclonal antibody against VEGF, was recently approved. Combinations of antiangiogenic drugs and conventional cytotoxic chemotherapy are currently under development.
Goudar
Ranjit K
RK
Department of Medicine, Duke University Medical Center, Box 3841, Durham, NC 27710, USA. rkg2@duke.edu
Vlahovic
Gordana
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002986:Clinical Trials as Topic; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000098:blood supply* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
Lung Cancer. 2006 Feb;51(2):143-58
16360975
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
Clin Cancer Res. 2007 Apr 1;13(7):1961-70
17404076
Ann Surg Oncol. 2004 Oct;11(10):928-33
15383417
Cancer Sci. 2007 Dec;98(12):1825-30
17892508
J Clin Oncol. 2007 Sep 20;25(27):4270-7
17878479
J Clin Oncol. 2004 Jun 1;22(11):2184-91
15169807
Crit Rev Oncol Hematol. 2007 May;62(2):93-104
17306557
Blood. 1999 Dec 15;94(12):4177-85
10590062
Clin Cancer Res. 2005 Sep 15;11(18):6459-65
16166420
Nat Med. 1995 Jan;1(1):27-31
7584949
Cancer Res. 1999 Dec 1;59(23):5863-70
10606224
Cancer Metastasis Rev. 2007 Jun;26(2):241-8
17440683
Br J Cancer. 2005 Aug 22;93(4):453-7
16091764
Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s
15217972
Clin Lung Cancer. 2007 May;8(6):396-8
17562243
Crit Rev Oncol Hematol. 2006 Oct;60(1):76-86
16843002
J Clin Oncol. 2007 Oct 20;25(30):4743-50
17909199
Oncologist. 2007 Oct;12(10):1183-93
17962612
J Clin Oncol. 2005 Apr 10;23(11):2544-55
15753462
J Cell Biol. 2001 Feb 19;152(4):777-84
11266468
Eur J Cancer. 2005 Dec;41(18):2828-35
16298124
J Clin Oncol. 2003 Jul 15;21(14):2645-50
12860939
Oncologist. 2007 Feb;12(2):191-200
17296815
Antioxid Redox Signal. 2007 Aug;9(8):1237-94
17571959
Anticancer Res. 1999 Jan-Feb;19(1B):651-5
10216471
Oncogene. 2007 May 28;26(25):3691-8
17530022
Br J Cancer. 2004 May 17;90(10):1877-81
15138464
Br J Cancer. 1955 Dec;9(4):539-49
13304213
Br J Cancer. 2002 Jan 21;86(2):244-9
11870514
Clin Cancer Res. 2006 Mar 1;12(5):1507-14
16533775
J Clin Oncol. 2006 Nov 20;24(33):5291-7
17114663
Lung Cancer. 2007 Sep;57(3):373-80
17513004
Lung Cancer. 2005 Sep;49(3):325-35
15935515
J Clin Oncol. 2006 Oct 20;24(30):4825-32
17050867
Curr Treat Options Oncol. 2007 Feb;8(1):15-27
17634832
J Clin Oncol. 2005 May 10;23(14):3243-56
15886312